Left Ventricular Ejection Fraction clinical trials at UCSF
1 research study open to eligible people
Left ventricular ejection fraction shows the percentage of blood leaving the heart each time it contracts. At UCSF, one study tests if levosimendan improves exercise ability in people with specific heart issues. This involves comparing it with a placebo to check its effectiveness.
Showing trials for
LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF
open to eligible people ages 18-85
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
San Francisco, California and other locations
Last updated: